Outcomes in World Health Organization Group II Pulmonary Hypertension: Mortality and Readmission Trends With Systolic and Preserved Ejection Fraction–Induced Pulmonary Hypertension-Reference-Cited by-同舟云学术

Outcomes in World Health Organization Group II Pulmonary Hypertension: Mortality and Readmission Trends With Systolic and Preserved Ejection Fraction–Induced Pulmonary Hypertension

Published:2014-07 Issue:7 Volume:20 Page:467-475
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

Salamon Jason N.,Kelesidis Iosif,Msaouel Pavlos,Mazurek Jeremy A.,Mannem Santhosh,Adzic Aleksandar,Zolty Ronald

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference51 articles.

1. Nouvelle classification clinique de l’hypertension pulmonaire [A new clinical classification of pulmonary hypertension];Simonneau;Bull Acad Natl Med,2009

2. Diagnosis, assessment, and treatment of non–pulmonary arterial hypertension pulmonary hypertension;Hoeper;J Am Coll Cardiol,2009

3. Pulmonary hypertension associated with left-sided heart disease;Oudiz;Clin Chest Med,2007

4. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation;Fang;J Heart Lung Transplant,2012

5. Pulmonary hypertension with left-sided heart disease;Guazzi;Nat Rev Cardiol,2010

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary hypertension associated to left heart disease: Phenotypes and treatment;European Journal of Internal Medicine;2024-08

2. Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction;American Journal of Physiology-Heart and Circulatory Physiology;2024-06-01

3. The Impact of Diabetes on Haemodynamic and Cardiometabolic Responses in Heart Failure With Preserved Ejection Fraction;Heart, Lung and Circulation;2024-03

4. The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets;Vascular Pharmacology;2023-08

5. Markers of right ventricular dysfunction predict 30-day adverse prognosis of pulmonary embolism on pulmonary computed tomographic angiography;Medicine;2023-07-14